SCHEMBL1572344

SCHEMBL1572344

O=C(c1ncsc1-c1ccccc1)N1C2C[C@H]2C[C@H]1CNC(=O)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
HCRTR1 O43613 11/20 0.41
HCRTR2 O43614 10/20 0.41
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
VHL P40337 2/20 0.35
ELOC Q15369 1/20 0.35
ELOB Q15370 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
THPO P40225 1/20 0.34
LMNA P02545 1/20 0.34
PMP22 Q01453 1/20 0.34
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572343 1.00 KDM4E (0.42) KDM4EHCRTR1HCRTR2CKS1BSKP1
SCHEMBL1572338 1.00 KDM4E (0.42) KDM4EHCRTR1HCRTR2CKS1BSKP1
SCHEMBL1764519 0.83 KDM4E (0.48) KDM4EHCRTR1HCRTR2VHLCYP1A2
SCHEMBL1764517 0.83 KDM4E (0.48) KDM4EHCRTR1HCRTR2VHLCYP1A2
SCHEMBL982644 0.81 HCRTR1 (0.44) KDM4EHCRTR1HCRTR2CKS1BSKP1
SCHEMBL982642 0.81 HCRTR1 (0.44) KDM4EHCRTR1HCRTR2CKS1BSKP1
SCHEMBL1571898 0.75 HCRTR1 (0.41) HCRTR1HCRTR2CYP1A2CYP3A4THPO
SCHEMBL1572231 0.75 HCRTR1 (0.46) HCRTR1HCRTR2
SCHEMBL1571545 0.75 HCRTR1 (0.68) HCRTR1HCRTR2
SCHEMBL1571546 0.75 HCRTR1 (0.68) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-26 US disclosed
EP-2094690-B1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2011-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CNR1 KDM4E 1064/4885HCRTR1 2/4885HCRTR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.